Kansarka beerka
Sannadihii u dambeeyay, dhacdooyinka iyo dhimashada kansarka beerka ee adduunka ayaa aad u sarreeyay. Wadamada soo koraya waxay xisaabiyaan qiyaastii 50% kiisaska kansarka beerka cusub sanad walba, iyo heerka dhacdooyinka burooyinka halista ah waa afaraad. Si kastaba ha ahaatee, bukaanada intooda badan ee qaba kansarka beerka waxay la xiriiraan cirrhosis, ama bukaanada intooda badan waxay gaareen marxaladda hore ee waqtiga cudurka, iyo qiyaastii 20%-30% bukaanada ayaa heli kara fursadaha qalliinka.
Waxaa jira daweyn badan oo loogu talagalay kansarka beerka, laakiin kansarka beerka waa adag tahay in la daweeyo
Surgery is the only way to cure liver cancer, and only early liver cancer has this opportunity. In addition to surgery, local treatment methods include surgery, transcatheter arterial chemoembolization, percutaneous radiofrequency ablation, and radiation therapy; systemic treatment includes chemotherapy, targeted therapy, and immunotherapy.
With the increasing number of treatments for liver cancer in recent years, precision surgical treatment combined with systemic targeted therapy (sorafenib, lervatinib, regorafenib, cabozantinib and ramozumab) and immunotherapy (Pimumab, Navumab), individualized combination therapy for patients, the treatment effect of advanced liver cancer is greatly improved.
Kiliinik ahaan, qiyaastii 90% bukaannada qaba kansarka beerka waxay leeyihiin taariikh cagaarshow B, 5% -8% bukaannada qaba kansarka beerka waxay qabaan cagaarshow C, qiyaastii 3% bukaannada ayaa lala xiriiriyaa cirrhosis oo ay keento khamriga joogtada ah, beerka dufanka leh. , iyo cudurada la xiriira cudurada beerka autoimmune.
Clinically, the curse of the three-step model (HBV-cirrhosis-liver kansarka) has always threatened many domestic liver cancer patients, making many cutting-edge treatment methods unable to improve the current status of liver cancer treatment. New therapies are urgently needed to solve the hepatitis B-related daaweynta kansarka beerka.
Ku qalabaynta unugyada T oo wata antigens-hubka gaarka ah oo cusub
Cilmi-baarayaasha Isbitaalka Qaranka ee Duke-Singapore ayaa naqshadeeyay Unugyada T-ga ee fayraska cagaarshowga B si ay u daweeyaan cagaarshowga nooca B-cagaarshow-cellalka kansarka, nooc ka mid ah kansarka beerka ee ku badan Aasiya.
Researchers have individualized T cells to make T cells specific to patients. I think this is a CAR-T-like cellular immunotherapy, which is to advance specific antigens of buro cells by technical means to activate them. T cells, after activated T cells are infused back into the body, it is like updating the weapon scouts to precisely attack cancer cells.
Kooxdu waxa ay ku guulaysteen in ay daaweeyaan laba bukaan oo beerka laga beddelay oo ay ku daweeyeen unugyo gaar ah oo T-unugyo ah, kuwaas oo laba ka mid ah ay hore u qabeen kansarka beerka ee fayraska cagaarshow B, haddana ay dib u soo noqdeen ka dib markii beerka laga beddelay. Ka dib daawaynta unugyada gaarka ah ee T, mid ka mid ah bukaannada ayaa arkay hoos u dhac ku yimid diiradda buro.
Bartilmaameedka antigen waa HBV-DNA
Daawaynta shakhsi ahaaneed, cilmi-baarayaashu waxay falanqeeyeen qaababka is-dhexgalka gaarka ah ee HBV-DNA ee unugyada kansarka ee bukaan-socod kasta oo kansarka beerka ah, ka dibna la baaray, naqshadeeyay oo la farsameeyay unugyada gaarka ah ee T, ka dibna la daaweeyay. In ka badan 20-ku- shubid unugyada T-cell ah ayaa si guul leh loogu sameeyay laba bukaan oo beerka laga beddelay, unugyadan T-da ee la farsameeyayna waxay awoodeen inay burburiyaan burooyinka.
Cilmi-baare sare, Antonio Bertoletti ayaa yiri: Qaybta Hidde-sidayaasha HBV-DNA ee isku dhafan waxay kicin karaan unugyada HBV-ga gaarka ah ee T waxayna dili karaan unugyada kansarka beerka ee gaarka ah iyada oo aan saameyn ku yeelan unugyada kale ee caafimaadka qaba. Ma jirin dareen-celin xun oo daawaynta la xidhiidha, iyo metastasis-ka fog ee kansarka beerka ee hal bukaan ayaa sidoo kale hoos u dhacay.
Kansarka sanbabada caused by chronic hepatitis B infection accounts for 80% of all liver cancers in Asian lung cancer, and the treatment prognosis is not ideal. Especially in patients with liver cancer recurrence after liver transplantation, treatment options are more limited.
Daaweynta unugyada gaarka ah ee T-da ee ay soo saartay Kuliyadda Caafimaadka Qaranka ee Singapore waxay wanaajin kartaa badbaadada iyo tayada nolosha bukaannada noocaan ah. Daaweynta unugyada CAR-T waa rajo cusub oo mustaqbalka lagaga adkaan karo kansarka!
Daaweynta unugyada CAR-T waa Chimeric Antigen Receptor T-Cell Immunotherapy. Kani waa nooc cusub oo ah daawaynta saxda ah ee lagu daweynayo burooyinka. Sanadihii la soo dhaafay, waxay ku guulaysatay natiijooyin wanaagsan daaweynta burooyinka kiliinikada iyada oo loo marayo hagaajin iyo hagaajin. Waa rajo aad u wanaagsan, sax ah, degdeg ah, hufan, oo suurtogal ah in lagu daweeyo kansarka. Daaweyn cusub oo buro ah.
Waxaa laga yaabaa inaad jeceshahay inaad akhriso: Baabuurka T-Cell therapy ee Hindiya
Daaweynta CAR-T waa habka daawaynta kansarka kaas oo gaadhay horumarro la taaban karo sanadihii ugu dambeeyay, waxaana u ansixiyay waaxaha caalamiga ah ee ay khusayso si loogu isticmaalo daawaynta burooyinka dhiiga. Intaa waxaa dheer, tijaabooyinka kiliinikada ee daaweynta unugyada CAR-T ee loogu talagalay burooyinka adag ayaa si xawli ah u socda.
